CA2913418C - Intracorps a chaine unique modifiant la degradation de la proteine mutante huntingtin - Google Patents

Intracorps a chaine unique modifiant la degradation de la proteine mutante huntingtin Download PDF

Info

Publication number
CA2913418C
CA2913418C CA2913418A CA2913418A CA2913418C CA 2913418 C CA2913418 C CA 2913418C CA 2913418 A CA2913418 A CA 2913418A CA 2913418 A CA2913418 A CA 2913418A CA 2913418 C CA2913418 C CA 2913418C
Authority
CA
Canada
Prior art keywords
sequence
seq
variable light
intrabody
variable heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2913418A
Other languages
English (en)
Other versions
CA2913418A1 (fr
Inventor
Lee Alan Henderson
Irene Alexandra AMARO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vybion Inc
Original Assignee
Vybion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vybion Inc filed Critical Vybion Inc
Publication of CA2913418A1 publication Critical patent/CA2913418A1/fr
Application granted granted Critical
Publication of CA2913418C publication Critical patent/CA2913418C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des compositions et des méthodes d'utilisation d'intracorps se liant et modifiant les effets de l'agrégation de protéines poly-glutamate dans des maladies associées au poly-glutamate, telles que la maladie de Huntington. Les intracorps selon l'invention empêchent l'agrégation de poly-glutamate, la dérégulation de gènes et les effets négatifs de la maladie de Huntington.
CA2913418A 2013-05-29 2014-05-09 Intracorps a chaine unique modifiant la degradation de la proteine mutante huntingtin Active CA2913418C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361828625P 2013-05-29 2013-05-29
US61/828,625 2013-05-29
US201361871288P 2013-08-28 2013-08-28
US61/871,288 2013-08-28
PCT/US2014/037563 WO2014193632A2 (fr) 2013-05-29 2014-05-09 Intracorps à chaîne unique modifiant la dégradation de la protéine mutante huntingtin

Publications (2)

Publication Number Publication Date
CA2913418A1 CA2913418A1 (fr) 2014-12-04
CA2913418C true CA2913418C (fr) 2021-11-23

Family

ID=51989509

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2913418A Active CA2913418C (fr) 2013-05-29 2014-05-09 Intracorps a chaine unique modifiant la degradation de la proteine mutante huntingtin

Country Status (8)

Country Link
US (3) US9932394B2 (fr)
EP (2) EP3950712A1 (fr)
CN (2) CN111205369B (fr)
AU (2) AU2014272024B2 (fr)
CA (1) CA2913418C (fr)
DK (1) DK3071598T3 (fr)
HK (1) HK1223634A1 (fr)
WO (1) WO2014193632A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193632A2 (fr) 2013-05-29 2014-12-04 Vybion, Inc. Intracorps à chaîne unique modifiant la dégradation de la protéine mutante huntingtin
WO2016005545A1 (fr) 2014-07-10 2016-01-14 Affiris Ag Substances et procédés à utiliser pour la prévention et/ou le traitement de la maladie de huntington
US10556946B2 (en) * 2014-07-29 2020-02-11 Neurimmunie Holding AG Human derived anti-Huntingtin (HTT) antibodies and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
ES2099980T3 (es) 1992-10-13 1997-06-01 Gilbarco Inc Aparato para efectuar transacciones.
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
DK0702721T3 (da) * 1993-06-09 2001-05-21 Unilever Nv Fremgangsmåde til fremstilling af fusionsproteiner, der omfatter ScFv fragmenter, ved hjælp af en transformeret skimmelsvamp
DK173897B1 (da) 1998-09-25 2002-02-04 Topsoe Haldor As Fremgangsmåde til autotermisk reforming af et carbonhydridfødemateriale indeholdende højere carbonhydrider
US7375194B2 (en) * 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
US7799986B2 (en) 2002-07-16 2010-09-21 Line 6, Inc. Stringed instrument for connection to a computer to implement DSP modeling
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
EP2094711B8 (fr) * 2006-09-25 2018-03-28 Forschungsverbund Berlin e.V. Structures mimétiques de peptides riches en proline, et leur utilisation pharmaceutique
WO2008151833A2 (fr) * 2007-06-13 2008-12-18 Hochschule Mannheim Composés pour la modulation de l'agrégation de l'huntingtine, procédés et moyens d'identification de tels composés
WO2013043669A1 (fr) * 2011-09-21 2013-03-28 The Board Of Regents Of The University Of Texas System Compositions peptoïdes pour le traitement de la maladie d'alzheimer et d'un trouble de l'expansion de polyglutamine
WO2014193632A2 (fr) 2013-05-29 2014-12-04 Vybion, Inc. Intracorps à chaîne unique modifiant la dégradation de la protéine mutante huntingtin

Also Published As

Publication number Publication date
HK1223634A1 (zh) 2017-08-04
US20220064269A1 (en) 2022-03-03
AU2014272024B2 (en) 2018-03-15
US9932394B2 (en) 2018-04-03
EP3950712A1 (fr) 2022-02-09
CA2913418A1 (fr) 2014-12-04
CN105531287A (zh) 2016-04-27
DK3071598T3 (da) 2021-09-13
EP3071598B1 (fr) 2021-07-07
CN111205369B (zh) 2024-03-08
AU2018204243B2 (en) 2020-10-15
CN111205369A (zh) 2020-05-29
US20170044241A1 (en) 2017-02-16
WO2014193632A3 (fr) 2015-04-02
EP3071598A2 (fr) 2016-09-28
AU2014272024A1 (en) 2015-12-03
US20180319874A1 (en) 2018-11-08
AU2018204243A1 (en) 2018-07-05
US11072650B2 (en) 2021-07-27
WO2014193632A2 (fr) 2014-12-04
EP3071598A4 (fr) 2017-06-14
CN105531287B (zh) 2020-01-21

Similar Documents

Publication Publication Date Title
US20220064269A1 (en) Single chain intrabodies that alter huntingtin mutant degradation
ES2321568T3 (es) Bibliotecas de fragmentos fab y procedimientos para su uso.
JP5719596B2 (ja) 抗体及びその誘導体
US9109223B2 (en) Methods for generating and screening fusion protein libraries and uses thereof
WO2006137354A1 (fr) Anticorps avec effet inhibiteur sur la formation de fibrilles amyloïdes
US20230029835A1 (en) Development and application of therapeutic agents for tslp-related diseases
JP7236562B2 (ja) インターロイキン－４受容体抗体及びその用途
CN114133450B (zh) 抗-Rho GTPase的构象单域抗体及其用途
EA023477B1 (ru) МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, СВЯЗЫВАЮЩЕЕ ДОМЕН γ-С ФИБРИНА ИЛИ ФИБРИНОГЕНА
US10202430B2 (en) IgM-mediated receptor clustering and cell modulation
US20200385450A1 (en) Therapeutic antibodies for treatment of neurodegeneration
EP3992205A1 (fr) Composés de liaison de protéine de spicule du sars coronavirus-2
CN113924315B (zh) 抗β-NGF纳米抗体及其应用
JP2013542720A (ja) 抗エフリン−ｂ２抗体およびその使用
EP3647426A1 (fr) Protéine de fusion
JP6029019B2 (ja) 細胞接着阻害剤、細胞増殖阻害剤、並びに癌の検査方法および検査用キット
EP2758077B1 (fr) Composés pour l'utilisation dans le traitement de la maladie d'alzheimer
BR102012011493A2 (pt) Método de produção e obtenção de fragmento fab do anticorpo anti-digoxina monoclonal a partir da técnica de clonagem em biologia molecular
CN117586388A (zh) 改进的β淀粉样蛋白寡聚体特异性结合抗体
KR20130140557A (ko) 항 ｉｌ-６ｒ 및 ｔｎｆｒ２을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 줄기세포 치료제
Dos Developing Synthetic Tools to Image and Modulate the Activity of Carboxyl terminus of Hsc70-Interacting Protein (CHIP)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190508